Abattis Bioceuticals Stock Price, News & Analysis (CNSX:ATT)

C$0.34 0.00 (0.00 %)
(As of 02/22/2018 04:00 PM ET)
Previous CloseC$0.34
Today's RangeC$0.34 - C$0.35
52-Week RangeC$0.05 - C$0.74
Volume1.25 million shs
Average Volume1.40 million shs
Market CapitalizationC$94.26 million
P/E Ratio-6.80
Dividend YieldN/A
BetaN/A

About Abattis Bioceuticals (CNSX:ATT)

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.

Receive ATT News and Ratings via Email

Sign-up to receive the latest news and ratings for ATT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolCNSX:ATT
CUSIPN/A
Phone+1-604-3360881

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-6.8
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($0.05)
Net IncomeN/A
Net MarginsN/A
Return on Equity-402.39%
Return on Assets-361.99%

Miscellaneous

EmployeesN/A
Outstanding Shares162,700,000

Abattis Bioceuticals (CNSX:ATT) Frequently Asked Questions

What is Abattis Bioceuticals' stock symbol?

Abattis Bioceuticals trades on the CNSX under the ticker symbol "ATT."

Who are Abattis Bioceuticals' key executives?

Abattis Bioceuticals' management team includes the folowing people:

  • Robert Abenante CPA, President, Chief Executive Officer, Director (Age 33)
  • David Whitney, Chief Financial Officer
  • Rene David, Chief Operating Officer, Director
  • Christopher P. Cherry, Corporate Controller (Age 40)
  • Hugh Oswald, IR Contact Officer
  • Christina Boddy, Corporate Secretary
  • Peter Gordon, Director
  • James Irving, Director
  • Shuang Xie, Director
  • Guy P. Dancosse QC, Independent Director

What is Abattis Bioceuticals' stock price today?

One share of Abattis Bioceuticals stock can currently be purchased for approximately C$0.34.

How big of a company is Abattis Bioceuticals?

Abattis Bioceuticals has a market capitalization of C$94.26 million.

How can I contact Abattis Bioceuticals?

Abattis Bioceuticals' mailing address is 224-970 Burrard St, VANCOUVER, BC V6Z 2R4, Canada. The company can be reached via phone at +1-604-3360881.


MarketBeat Community Rating for Abattis Bioceuticals (ATT)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  39
MarketBeat's community ratings are surveys of what our community members think about Abattis Bioceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abattis Bioceuticals (CNSX:ATT) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for Abattis Bioceuticals (CNSX:ATT)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Abattis Bioceuticals (CNSX:ATT) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Abattis Bioceuticals (CNSX:ATT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Abattis Bioceuticals (CNSX ATT) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Abattis Bioceuticals (CNSX:ATT)

Abattis Bioceuticals (CNSX ATT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/19/2018William PanenkaDirectorSell90,000C$0.59C$53,100.00
1/16/2018William PanenkaDirectorSell25,000C$0.67C$16,750.00
1/12/2018William PanenkaDirectorSell90,000C$0.53C$47,700.00
12/15/2017Shuang XieDirectorSell50,000C$0.66C$33,000.00
12/12/2017Rene DavidInsiderSell66,000C$0.46C$30,360.00
12/12/2017William PanenkaDirectorSell100,000C$0.48C$48,000.00
11/28/2017Shuang XieDirectorSell10,000C$0.32C$3,200.00
(Data available from 1/1/2013 forward)

Headlines

Abattis Bioceuticals (CNSX ATT) News Headlines

Source:
DateHeadline
Abattis Enters Into Definitive Agreement to Acquire 49% Stake In CannaNUMUS Blockchain - GlobeNewswire (press release)Abattis Enters Into Definitive Agreement to Acquire 49% Stake In CannaNUMUS Blockchain - GlobeNewswire (press release)
globenewswire.com - February 2 at 8:58 AM
Abattis Bioceuticals Corp (ATT) Director William Panenka Sells 90,000 SharesAbattis Bioceuticals Corp (ATT) Director William Panenka Sells 90,000 Shares
www.americanbankingnews.com - January 22 at 3:24 PM
Abattis Bioceuticals Corp (ATT) Director William Panenka Sells 25,000 SharesAbattis Bioceuticals Corp (ATT) Director William Panenka Sells 25,000 Shares
www.americanbankingnews.com - January 19 at 4:46 PM
Abattis Bioceuticals Corp (ATT) Director Sells C$47,700.00 in StockAbattis Bioceuticals Corp (ATT) Director Sells C$47,700.00 in Stock
www.americanbankingnews.com - January 19 at 4:24 PM
Looming Legalization has Cannabis Producers Thinking Outside the Dispensary - Baystreet.caLooming Legalization has Cannabis Producers Thinking Outside the Dispensary - Baystreet.ca
www.baystreet.ca - January 12 at 8:21 AM
Abattis Enters Into Definitive Agreement to Acquire Green Tree Therapeutics - GlobeNewswire (press release)Abattis Enters Into Definitive Agreement to Acquire Green Tree Therapeutics - GlobeNewswire (press release)
globenewswire.com - January 12 at 8:21 AM
IIROC Trading Halt - ATTIIROC Trading Halt - ATT
finance.yahoo.com - January 9 at 6:52 PM
IIROC Trade Resumption - ATTIIROC Trade Resumption - ATT
finance.yahoo.com - January 9 at 6:52 PM
This BioTech Stock Could Be Poised for a Breakout in 2018 - Baystreet.caThis BioTech Stock Could Be Poised for a Breakout in 2018 - Baystreet.ca
www.baystreet.ca - December 21 at 6:33 PM
Abattis Announces Expansion of Northern Vine Dealers License ... - NasdaqAbattis Announces Expansion of Northern Vine Dealer's License ... - Nasdaq
www.nasdaq.com - December 19 at 8:10 AM
Abattis Announces Expansion of Northern Vine Dealers License - GlobeNewswire (press release)Abattis Announces Expansion of Northern Vine Dealer's License - GlobeNewswire (press release)
globenewswire.com - December 19 at 8:10 AM
Abattis Bioceuticals Corp (ATT) Director Shuang Xie Sells 50,000 SharesAbattis Bioceuticals Corp (ATT) Director Shuang Xie Sells 50,000 Shares
www.americanbankingnews.com - December 18 at 6:50 PM
Rene David Sells 66,000 Shares of Abattis Bioceuticals Corp (ATT) StockRene David Sells 66,000 Shares of Abattis Bioceuticals Corp (ATT) Stock
www.americanbankingnews.com - December 13 at 2:36 PM
William Panenka Sells 100,000 Shares of Abattis Bioceuticals Corp (ATT) StockWilliam Panenka Sells 100,000 Shares of Abattis Bioceuticals Corp (ATT) Stock
www.americanbankingnews.com - December 13 at 2:34 PM
Abattis Confirms Breakthrough Extraction Technology Capabilities - GlobeNewswire (press release)Abattis Confirms Breakthrough Extraction Technology Capabilities - GlobeNewswire (press release)
globenewswire.com - December 13 at 8:10 AM
"Aphria Inc." (ATT) Director Shuang Xie Sells 50,000 Shares"Aphria Inc." (ATT) Director Shuang Xie Sells 50,000 Shares
www.americanbankingnews.com - November 27 at 8:40 PM

SEC Filings

Abattis Bioceuticals (CNSX:ATT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Abattis Bioceuticals (CNSX ATT) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.